INCY · Incyte Corp
Price
Snapshot
50 fields · last close| Market Cap | $22.92B |
| P/E | 14.21 |
| Float | 198.7M |
| Beta | 0.79 |
| Volatility | 19.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 77.1 |
| Price | 113.51 |
| Change | +0.39% |
| Prev Close | 113.07 |
| Open | 113.98 |
| Day Low | 112.02 |
| Day High | 114.57 |
| Avg Vol | 2 |
| Avg $ Vol | $205.7M |
| 52W High | 132.60 |
| 52W Low | 84.02 |
| 52W Pos | 60.7% |
| From High | −14.40% |
| From Low | +35.10% |
| Max DD 1Y | −18.33% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −3.40% |
| SMA 50 | −6.83% |
| SMA 200 | +5.59% |
| RSI (14) | 39.4 |
| Vol 30D | 24.7% |
| Vol 90D | 33.7% |
| 1Y Range | 84–133 |
| Daily bars | 536 |
| Perf Week | +0.25% |
| Perf Month | −11.40% |
| Perf Quarter | −2.23% |
| Perf Half Y | +15.59% |
| Perf Year | +28.27% |
| Perf YTD | +11.92% |
| Prev Day | +0.39% |
| Clavix | B+ |
| Debt / Eq | 3.69 |
| Curr Ratio | 3.32 |
| Int Cover | 12.4× |
| FCF Margin | 27.5% |
| Rev Growth | +21.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 9 / 35 |
What INCY does
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive.
It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Clavix risk grade
regraded every trading dayINCY grades B+, 77.1 of 100. Steadiest on News Sentiment (68), most exposed on Sector Resilience (56, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 9 of 35 in Biotechnology by Clavix score.
How rough the ride is
| INCY | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.79 | 0.51 |
| Volatilityannualized | 19.8% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −18.3% | — |
| Typical daily movemedian absolute daily change | 1.19% | — |
| Days beyond ±3%of the last 252 sessions | 25 (10%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| INCY | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.79 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| INCY | |
|---|---|
| 1 week | +0.2% |
| 1 month | −11.4% |
| Year to date | +11.9% |
| 1 year | +28.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| INCY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 1 Aug |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 3 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| INCY | |
|---|---|
| Revenue growthyear over year | +21.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openIncyte has disclosed new patents covering pyrazole-fused compounds designed to block VRK1, a cell-division protein some cancers rely on, as potential cancer treatments.
The FDA approved Atebrioz (zilurgisertib), developed by Mirum and Incyte, to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder where muscles and connective tissue gradually turn into bone, in adults and children. The article also notes a separate Phase 3 trial result for a different drug, brelovitug, which belongs to Mirum rather than Incyte.
The FDA approved Atebrioz (zilurgisertib), a once-daily pill for fibrodysplasia ossificans progressiva (FOP), a rare disease where muscles and connective tissue progressively turn into bone. Mirum Pharmaceuticals and Incyte announced the approval, which covers patients 12 and older.
Analyst firm HC Wainwright raised its price target on Incyte (INCY) from $150 to $152 and gave the stock a 'buy' rating. The article is very short and does not explain the reasoning behind the change.
The FDA approved Atebrioz (zilurgisertib), a drug developed by Mirum Pharmaceuticals together with Incyte, to treat fibrodysplasia ossificans progressiva (FOP), a rare disease where muscles and connective tissue gradually turn into bone, in patients aged 12 and older. The article does not provide further detail on financial terms, launch timing, or pricing.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
| INSM | Insmed Inc | C | $21.02B | — | 0.83 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| EXEL | Exelixis Inc | B+ | $15.42B | 17.92 | 0.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.05B | 16.85 | 0.39 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $13.83B | 33.44 | 0.93 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $13.79B | 19.55 | 0.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.